Key result
IV cangrelor compares similarly to oral P2Y12 inhibitors for periprocedural antiplatelet therapy.
Why the study?
The clinical advantages of intravenous cangrelor compared to oral P2Y12 inhibitors during periprocedural antiplatelet therapy in cardiovascular and neurovascular interventions were unclear.
Comparison
Intravenous cangrelor versus oral P2Y12 inhibitors (ticagrelor, prasugrel)
Design
Other
Answers are grounded in this paper and cite their sources.
Comparative study reports clinical outcomes of intravenous versus oral P2Y12 inhibitors in vascular procedures, highlighting periprocedural antiplatelet optimization.
To evaluate whether intravenous (IV) cangrelor offers clinical advantages over oral P2Y12 inhibitors (ticagrelor, prasugrel) in periprocedural antiplatelet therapy during cardiovascular and neurovascular interventions.
No takes yet. Share an insight, caveat, or question.
Julius et al. (2026) studied this question. Intravenous cangrelor was compared to oral P2Y12 inhibitors to evaluate clinical outcomes during periprocedural antiplatelet therapy in cardiovascular and neurovascular interventions.
Synapse has enriched 5 related papers. Consider them for comparative context: